SUVEN LIFE SCIENCES LTD. SHARE PRICE [LIVE]
| Open: | |
| High: | |
| Low: |
| MKT Cap: | |
| 52-wk High: | |
| 52-wk Low: |
| Prev close: | |
| P/E: | |
| Div yield: |
Fundamental analysis
What is not working for the company?
What is working for the company?
| Name | Dec 22 | Nov 22 |
|---|---|---|
| Promoters (Change:4.59) | 69.57% | 64.98% |
| FIIs (Change:-0.04) | 0.45% | 0.49% |
| Mutual Funds (Change:-0.00) | 0.01% | 0.01% |
| Insurance Companies (Change:0.00) | 0% | 0% |
| Other DIIs (Change:0.00) | 0.1% | 0.1% |
| Non Institution (Change:-4.55) | 29.87% | 34.42% |
Similar Stocks
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in SUVEN LIFE SCIENCES LTD.
Months ago
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
SUVEN News
Frequently Asked Questions
What is the Share price of SUVEN LIFE SCIENCES LTD. (SUVEN)?
Can I buy SUVEN LIFE SCIENCES LTD. (SUVEN) shares?
How do I buy SUVEN LIFE SCIENCES LTD. (SUVEN) from Angel One?
- Direct investment: You can buy SUVEN LIFE SCIENCES LTD. (SUVEN) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to SUVEN LIFE SCIENCES LTD. (SUVEN) shares.
In which sector do SUVEN LIFE SCIENCES LTD. (SUVEN) belong?
About SUVEN
Today's live share price for SUVEN LIFE SCIENCES LTD. is NSE: ₹ 46.95, BSE: ₹ 46.39 with a current market capitalization of .
Incorporated in Mar.'89 as a private limited company, Suven Pharmaceuticals (SPL) was converted into a public limited company in Jan.'95. It was promoted by Jasti Sudha Rani and Jasti Venkateswarlu, who is the present managing director. In Mar.'95, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. The company manufactures bulk drugs and drug intermediates -- theophylline, caffeine, nitroso compound, cyanoacetic acid, etc. SPL has a sizeable export turnover through the export of drug intermediates to Germany, Switzerland, Israel, Europe, etc. During 1999-2000, the company has acquired a small pilot plant in Jeedimetla Industrial Estate,Hyderabad. During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 has registered a growth of 71% over the previous year.The Profit After Tax(PAT) has also registered a growth of 325% over the previous year. The company has successfully achieved the re-certification of ISO 9002 during the year 2000-01. The company is planning to Modernize & Upgrade its R & D at Jeedimetla Industrial Estate.
Read more
